Use of Bridge-1 and activators and inhibitors thereof in the treatment of insulin deficiency and diabetes
US7875275B2 · kind B2 · utility
0Cited by
2References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 16, 2005 |
| Grant date | Jan 25, 2011 |
| Priority date | — |
| Expiry date | Jun 16, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2501/33
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to the use of Bridge-1 polynucleotides and Bridge-1 polypeptides, as well as activators and inhibitors of Bridge-1 activity, in the treatment of Bridge-1 mediated disorders, including diabetes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.